Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.

Authors:
Michael Fiegl Andreas Falkner Georg Hopfinger Stefan Brugger August Zabernigg Franz Bauer Ferdinand Haslbauer Dita Demirtas Peter Grossschmidt Georg Tatzreiter Günther Gastl Richard Greil

Cancer 2006 Nov;107(10):2408-16

Department of Internal Medicine, Division of Hemato-Oncology, University Hospital of Innsbruck, Innsbruck, Austria.

Background: In previous studies, alemtuzumab demonstrated considerable activity in patients with previously treated B-cell chronic lymphocytic leukemia (CLL), including fludarabine-refractory disease. In this retrospective study, the authors evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced, previously treated CLL who received treatment in the routine clinical setting.

Methods: Data were collected from 115 consecutive patients who received alemtuzumab therapy at 25 participating centers in Austria. Patients received a median of 3 prior lines of therapy (range, 1-11 prior lines of therapy), and 59% had fludarabine-refractory disease. Alemtuzumab was administered intravenously or subcutaneously with a planned schedule of 30 mg 3 times per week for up to 12 weeks. Patients received valacyclovir and trimethoprim/sulfamethoxazole for antiinfective prophylaxis.

Results: The overall response rate was 23%, with complete responses achieved in 5% of patients. Stable disease (SD) was achieved in 36% of patients. After a median follow-up of 17.5 months, the median overall survival (OS) was 20.2 months for all patients. A multivariate Cox regression analysis that included pretreatment baseline characteristics, response to therapy, and cumulative dose of alemtuzumab indicated that bulky lymphadenopathy, the administration of > r =3 previous therapies, and lack of response to alemtuzumab remained significant independent risk factors for inferior OS. The median OS had not been reached for responding patients. The median OS was 29.5 months for patients with SD and 10.8 months for patients with progressive disease.

Conclusions: The broad use of alemtuzumab in the routine clinical practice setting is feasible and active in unselected patients with pretreated CLL, and the current results confirmed the activity and safety of this agent, as reported in previously published clinical studies.

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.22263DOI Listing
November 2006

Publication Analysis

Top Keywords

patients
13
months patients
12
patients received
12
routine clinical
12
fludarabine-refractory disease
8
unselected patients
8
chronic lymphocytic
8
lymphocytic leukemia
8
retrospective study
8
patients median
8
b-cell chronic
8
alemtuzumab
8
lines therapy
8
prior lines
8
median
5
disease achieved
4
175 months
4
months median
4
months
4
achieved 36%
4

Keyword Occurance

Similar Publications

Characteristics, presentation and outcomes of music festival patrons with stimulant drug-induced serotonin toxicity.

Authors:
Lachlan F Miles Kristy Austin Alan Eade David Anderson Andis Graudins Forbes McGain Jacqueline Maplesden Shaun Greene Joe-Anthony Rotella Martin Dutch

Emerg Med Australas 2021 Apr 15. Epub 2021 Apr 15.

Clinical Services, St John Ambulance Australia, Melbourne, Victoria, Australia.

Objective: A large number of stimulant drug-associated deaths at music festivals in Australia were reported during the southern hemisphere summer of 2018-2019. This led to the prehospital deployment of healthcare professional-led critical care response teams. We aimed to describe the characteristics, clinical presentation, management and outcomes of music festival patrons with stimulant drug-induced serotonin toxicity managed using this model during the study period. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Germline mutations and age at onset of lung adenocarcinoma.

Authors:
Karen L Reckamp Carolyn E Behrendt Thomas P Slavin Stacy W Gray Danielle K Castillo Marianna Koczywas Mihaela C Cristea Kirsten M Babski Donna Stearns Catherine A Marcum Yenni P Rodriguez Amie J Hass Mary M Vecchio Pamela Mora Aleck E Cervantes Sharon R Sand Rosa M Mejia Terrence C Tsou Ravi Salgia Jeffrey N Weitzel

Cancer 2021 Apr 15. Epub 2021 Apr 15.

City of Hope Comprehensive Cancer Center, Duarte, California.

Background: To identify additional at-risk groups for lung cancer screening, which targets persons with a long history of smoking and thereby misses younger or nonsmoking cases, the authors evaluated germline pathogenic variants (PVs) in patients with lung adenocarcinoma for an association with an accelerated onset.

Methods: The authors assembled a retrospective cohort (1999-2018) of oncogenetic clinic patients with lung adenocarcinoma. Eligibility required a family history of cancer, data on smoking, and a germline biospecimen to screen via a multigene panel. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

[Diagnosis and therapy of cerebral venous and sinus thrombosis].

Authors:
Christian Weimar

Fortschr Neurol Psychiatr 2021 Apr 15;89(4):182-194. Epub 2021 Apr 15.

Although cerebral venous and sinus thrombosis (CVST) is a rare cerebrovascular disease, it is being diagnosed with increasing frequency due to increased clinical awareness, better imaging capabilities, and higher survival rates in patients with predisposing conditions. This article shows how the diagnosis can be made effectively and what therapeutic options exist in the acute phase and secondary prophylaxis. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

[Oncological Rehabilitation and Development of Strategies in Crisis Situations Using the Example of the Covid 19 Pandemic in 2020 by Using a Patient and Staff Survey Results of Pandemic Care].

Authors:
Birgit Leibbrand Ulf Seifart

Rehabilitation (Stuttg) 2021 Apr 15;60(2):142-151. Epub 2021 Apr 15.

Klinik Sonnenblick der Deutschen Rentenversicherung Hessen, Marburg.

Introduction: Cancer is a life-threatening disease often with curative therapy approaches, high risk of relapse and distressing symptoms, which require immediate, quality-assured care throughout the entire therapy process including rehabilitation, even in a pandemie.

Methods: We started to develop a pandemic plan to maintain oncological rehabilitation in February 2020. With the involvement of the whole clinic staff we developed protection scenarios with the aim of achieving Covid-19-free clinics. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

[Development of a Psychosocial Online Self-Help Program for Cancer Patients: A Patient-Oriented Approach].

Authors:
Anna Mayer Angeliki Tsiouris Charlotte Nölke Tamara Schwinn Jörg Wiltink Manfred E Beutel Rüdiger Zwerenz

Rehabilitation (Stuttg) 2021 Apr 15;60(2):132-141. Epub 2021 Apr 15.

Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz.

Aim Of The Study: Involving potential end users in the development process of digital interventions makes it possible to ensure that these programs meet the needs, requirements and expectations of future users, which in turn has a positive impact on acceptance and adherence. This contribution presents a participatory development approach for the patient-centered design of the psycho-oncological online self-help , which aims to provide support in coping with cancer.

Methods: Patients were involved in the developmental process at two points. Read More

View Article and Full-Text PDF
April 2021
Similar Publications